Several medications can ease opioid withdrawal, and they fall into two categories: opioid-based medications that taper the body off its dependence gradually, and non-opioid medications that target specific withdrawal symptoms like anxiety, sweating, and muscle aches. The American Society of Addiction Medicine recommends using medications over abrupt cessation of opioids, and the choice between them depends on the treatment setting, the patient’s history, and personal preference.
Methadone for Managed Tapering
Methadone is a long-acting opioid that reduces withdrawal symptoms without producing the intense high of shorter-acting opioids. In a detox setting, it’s typically started at 10 to 20 mg by mouth and adjusted upward until withdrawal symptoms are controlled, usually around 40 mg per day. Federal regulations cap the first dose at 30 mg and the total first-day dose at 40 mg. From there, the dose is increased by no more than 10 mg every five days if symptoms persist.
For short-acting opioids like heroin or oxycodone, methadone tapers typically run 6 to 10 days, with the daily dose decreasing gradually. One important limitation: methadone-based withdrawal management must take place in an inpatient setting or a licensed opioid treatment program. You can’t get a methadone prescription for at-home detox the way you can with some other medications.
Buprenorphine: The Most Flexible Option
Buprenorphine (often combined with naloxone and sold as Suboxone) is a partial opioid that activates the same brain receptors as full opioids but with a ceiling effect, meaning its effects plateau at higher doses. This makes it safer and harder to misuse than methadone. It’s FDA-approved for opioid use disorder and can be prescribed in outpatient settings, which makes it the most accessible option for many people.
Timing matters with buprenorphine. You need to be in mild to moderate withdrawal before taking the first dose. If you take it too soon, while a full opioid is still active in your system, it can actually trigger what’s called precipitated withdrawal, a sudden and intense worsening of symptoms. Clinicians use a scoring tool called the Clinical Opiate Withdrawal Scale (COWS) to gauge readiness. Most protocols require a minimum score of 8 before starting, though some guidelines recommend waiting until the score reaches 11 or 12.
Buprenorphine can be used for short-term detox or transitioned into longer-term maintenance treatment, which significantly reduces the risk of relapse.
Lofexidine: The First Non-Opioid FDA-Approved Option
Lofexidine (brand name Lucemyra) became the first non-opioid medication approved by the FDA specifically for opioid withdrawal symptoms when it was approved in May 2018. It works by dialing down the surge of norepinephrine, a stress chemical, that drives many of the most uncomfortable withdrawal symptoms. When you stop taking opioids, your brain’s stress response goes into overdrive. Lofexidine calms that response, reducing anxiety, muscle aches, sweating, runny nose, and cramping.
It’s important to understand what lofexidine does and doesn’t do. It treats withdrawal symptoms, but it is not a treatment for opioid use disorder itself. It’s designed as a bridge: something to get you through acute withdrawal before starting longer-term treatment with buprenorphine, naltrexone, or methadone.
Clonidine: Widely Used but Not FDA-Approved
Clonidine works through the same general mechanism as lofexidine. It’s an older blood pressure medication that reduces the norepinephrine surge during withdrawal. Despite lacking FDA approval for this specific use, ASAM includes clonidine in its guidelines as a consensus-supported option, and it’s one of the most commonly used medications in withdrawal management.
Clonidine helps with anxiety, agitation, muscle aches, sweating, runny nose, and cramping. The main drawback compared to lofexidine is a higher rate of side effects, particularly low blood pressure and dizziness. A systematic review comparing the two found they were roughly equivalent in controlling withdrawal symptoms, but three of the included studies showed clonidine caused significantly more hypotension and general feelings of unwellness. There is also no established dosing regimen for clonidine in this context, so dosing tends to vary between providers.
Medications for Specific Symptoms
Withdrawal produces a constellation of symptoms, and clinicians often add targeted medications alongside the primary ones listed above. ASAM guidelines specifically mention combining clonidine with:
- Anti-diarrheal medications (like loperamide) for the GI symptoms that are common during withdrawal
- Anti-nausea medications for vomiting
- Pain relievers such as acetaminophen or ibuprofen for muscle and joint aches
- Sleep aids for the insomnia that often peaks in the first several days
- Anti-anxiety medications for acute anxiety, used cautiously and short-term
These supportive medications don’t treat the underlying withdrawal process, but they can make the difference between someone completing detox and leaving early because the discomfort is unbearable.
Naltrexone After Withdrawal
Naltrexone works differently from every other medication on this list. Instead of activating opioid receptors or calming the stress response, it blocks opioid receptors entirely. This means it prevents opioids from having any effect if you use them, which helps prevent relapse. The extended-release injectable form (Vivitrol) is given as a 380 mg injection once a month by a healthcare provider.
Naltrexone is not used during withdrawal. It’s used after withdrawal is complete. Because it blocks opioid receptors, taking it while opioids are still in your system will trigger severe precipitated withdrawal. You need to be completely opioid-free for a minimum of 7 to 10 days before starting naltrexone. Some clinicians use a naltrexone-facilitated approach to speed up the transition, but ASAM recommends this only be done by experienced clinicians and without anesthesia or heavy sedation.
What to Avoid
One approach that is explicitly not recommended is ultrarapid opioid detoxification, sometimes called UROD, which involves putting patients under general anesthesia while administering opioid-blocking drugs. ASAM advises against it due to a high risk of serious adverse events, including death. Stopping opioids abruptly without any medication support is also discouraged, as it increases both suffering and the likelihood of returning to opioid use.